Life Sciences

Overview

Working with clients in the life sciences demands skill sets across a wide range of practice areas. Our lawyers bring expertise in corporate law, mergers and acquisitions, private and public financing transactions, collaborations, technology transfer, licensing, regulatory matters and intellectual property law.  In addition, members of our life sciences group hold relevant degrees in experimental medicine, biochemistry, pharmacy, veterinary medicine, pharmacology and epidemiology.

Our life sciences group works with private and public life sciences companies, from start-ups to industry leaders. We understand the life cycle of these companies and have designed our practice to anticipate and address needs at every stage.  We also represent many clients on the buy-side in this sector, including private equity groups, venture capital funds, angel investors and investment banks focused on the life sciences sector.  We are able to help our clients (life sciences companies, research institutes, investors) identify possible opportunities within our business network.  We have been counsel in many of the notable M&A transactions within the life sciences sector in Canada and have advised on IPOs, financings and strategic collaboration arrangements. 

Canada’s unique life sciences sector features a public/private infrastructure mix; domestic and cross-border sources of private capital; distinct local and provincial funding incentives; SR&ED tax credits available for research conducted in Canada; and intricate cross-border tax concerns.  We have helped to structure many precisely designed cross-border research initiatives that are able to take full advantage of available federal and provincial research incentives.

We are strategically situated in the major English and French-speaking R&D hubs of Toronto, Ottawa and Montréal to help guide investors, emerging and established companies and research organizations at and through all stages of growth.

Lawyers in our life sciences group are also key players in our venture capital practice.  We draw upon our significant experience in VC, tax and other capital markets work to help our life sciences clients structure and complete financing transactions (whether private, PIPE or other public deals).  We have worked closely with scientific teams and early stage investors to establish early stage companies designed to commercialise research previously conducted in some of Canada’s world-class research institutes.  In addition to working with Canadian funds, we also advise various U.S. funds on their Canadian investing and in connection with exit transactions.

DownloadDownload

Related Expertise

Mark Austin

Partner, Commercial
Toronto

Shahir Guindi

National Co-chair
Montréal
  • Deep Genomics

    Deep Genomics in its Series A financing round of approximately US$13 million

  • Afexa Life Sciences Inc.

    The Special Committee to the Board of Directors of Afexa Life Sciences Inc., on the management of a $56 million hostile bid from Paladin Labs Inc. and the $76 million sale of the company to Valeant Pharmaceuticals International Inc.

  • Preferred share investors

    Preferred share investors in Epocal in the structured acquisition transaction pursuant to which Inverness Medical Innovations agreed to acquire Epocal.

  • Fate Therapeutics

    Fate Therapeutics in its acquisition of Verio Therapeutics and its establishment of an Ontario-based research company to pursue stem-cell based regenerative medicine.

  • Genesys Capital

    Genesys Capital in its acquisition of certain portfolio positions of New Generation Biotech (Equity) Fund. and Biotech Breakthrough Fund (I).

  • Genzyme

    Genzyme in its $580 million acquisition of AnorMED.

  • Jubilant Organosys

    Jubilant Organosys (of India) in its $250 million acquisition of DRAXIS Pharma, a company previously listed on NASDAQ and the TSX.

  • Preferred share investors

    Preferred share investors in Neuromed Pharmaceuticals in its merger of equals with CombinatoRx.

  • Natus Medical 

    Natus Medical in its acquisition of XLTEK for approximately $62.5 million.

  • Topigen Pharmaceuticals

    Topigen Pharmaceuticals in its sale to Pharmaxis (of Australia).

  • Find More